Recently, Sanofi (SNY) and partner, Regeneron Pharmaceuticals Inc. (REGN) received some encouraging news with the European Medicines Agency's (:EMA) Committee for Medicinal Products for Human Use ...
French pharma giant Sanofi (SNY) recently announced that detailed data on Zaltrap (aflibercept) from the pivotal phase III VELOUR study was published in the Journal of Clinical Oncology’s (JCO) ...
On Aug. 3, the FDA approved Zaltrap (ziv-aflibercept) for treating patients with metastatic colorectal cancer and tumors that have progressed or are resistant to oxaliplatin-containing therapies. The ...
U.S. regulators have stamped an approval as expected on Sanofi ($SNY) and Regeneron's ($REGN) drug Zaltrap for patients with aggressive cases of colorectal cancer ...
Sanofi and Regeneron opened their update on the cancer drug Zaltrap (aflibercept) on a sweet note: The FDA has granted a priority review of their new drug application for colorectal cancer. But the ...
Sanofi ($SNY) has put Zaltrap on sale for 50% off. The colorectal cancer drug isn't an overstock, but a brand-new product, approved by FDA in August. Like most new ...
Sanofi ($SNY) got its first green light for Zaltrap, a cancer drug developed with Regeneron ($REGN). It's a second-line approval, in a market already dominated by ...
PARIS (Reuters) - Sanofi and Regeneron Pharmaceuticals said their Zaltrap drug candidate failed to meet targets in a late-stage study for the treatment of prostate cancer, though U.S. authorities were ...
(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) ...
The Food and Drug Administration just announced that it approved Zaltrap for colorectal cancer, giving Tarrytown, N.Y.-based Regeneron its third approved drug -- an impressive achievement. . Regeneron ...
French pharma giant Sanofi ( SNY) recently announced that detailed data on Zaltrap (aflibercept) from the pivotal phase III VELOUR study was published in the Journal of Clinical Oncology's (JCO) ...
French pharma giant Sanofi (SNY) recently announced that detailed data on Zaltrap (aflibercept) from the pivotal phase III VELOUR study was published in the Journal of Clinical Oncology’s (JCO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results